Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017
December 14 2017 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of immunotherapy products, announces that the
Company will release financial results for the fiscal year ended
October 31, 2017 on Wednesday, December 20, 2017.
Advaxis’ senior management will host a conference call to review
its financial results and provide a business update, which will
include a discussion of the advantages of its Lm-based antigen
delivery platform and clinical pipeline. The conference call and
live audio webcast will begin at 10:00 a.m. Eastern time on
Thursday, December 21, 2017.
Conference Call & Webcast
Information
WHEN: Thursday, December 21, 2017 at 10:00 a.m. Eastern
time.DOMESTIC DIAL-IN: (844) 348-6133INTERNATIONAL DIAL-IN: (631)
485-4564CONFERENCE ID: 4682169WEBCAST:
www.ir.advaxis.com/news-events
For those unable to participate in the live conference call or
webcast, a digital recording will be available beginning December
21, 2017 two hours after the close of the conference call. To
access the recording, dial (855) 859-2056 or (404) 537-3406 and
provide the operator with the conference ID: 4682169. In addition,
the audio webcast will be archived on the Company’s website for a
period of time at www.ir.advaxis.com/news-events.
About Advaxis, Inc.
Advaxis, Inc., located in Princeton N.J., is a late-stage
biotechnology company focused on the discovery, development and
commercialization of proprietary Lm-based antigen delivery
products. These immunotherapies are based on a platform technology
that utilizes live attenuated Listeria monocytogenes (Lm)
bioengineered to secrete antigen/adjuvant fusion proteins.
These Lm-based strains are believed to be a significant
advancement in immunotherapy as they integrate multiple functions
into a single immunotherapy and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T-cell immunity,
activate the immune system with the equivalent of multiple
adjuvants, and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T-cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and pre-clinical
development: HPV-associated cancers, prostate cancer, neoantigen
therapy and hotspot mutation therapy.
To learn more about Advaxis, visit www.advaxis.com and
connect on Twitter, LinkedIn, Facebook,
and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2016, which is available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171214005065/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian
Hyland, 908-325-3891Bhyland@sternstrategy.comorRachel Auerbach,
908-325-3898Rauerbach@sternstrategy.comorInvestors:LHA
Investor RelationsAnne Marie Fields,
212-838-3777afields@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024